OTLK Share Price Performance
US$0.76
-2.01 (-72.69%)
52.7% undervalued intrinsic discount
US$1.60
Fair Value
Price US$0.76
AnalystLowTarget US$1.60
Fair ValueUS$1.60
Share Pricen/a
New Narrative • Aug 14
Outlook Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 32 Fair Values set on narratives written by author
OTLK Community Narratives
AN
Fair Value
·Fair Value US$1.6 52.7% undervalued intrinsic discount
Compounded Bevacizumab Reliance Will Pressure Retina Pricing Yet Long Term Outlook Remains Constructive
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Compounded Bevacizumab Reliance Will Pressure Retina Pricing Yet Long Term Outlook Remains Constructive
Outlook Therapeutics has a rare advantage in eye care with a newly approved version of a drug many retina doctors already use, but cheap pharmacy-made alternatives and insurer rules may keep patients from switching quickly. The story hinges on whether coverage decisions, competition from newer treatments, and rising sales costs leave enough room for adoption to build over time.Read more
AN
US$1.6
52.7% undervalued intrinsic discount
Fair Value
Profit Margin
30.63%
Future PE
9.31x
Price in 2029
US$1.11
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Compounded Bevacizumab Reliance Will Pressure Retina Pricing Yet Long Term Outlook Remains Constructive
Fair Value: US$1.6 52.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Outlook Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.33
- 195.69%
- 5,258.04%
- -93.0%
About OTLK
- Founded
- 2010
- Employees
- 17
- CEO
- WebsiteView website
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
